Richard Laing, Kelly McGoldrick

Slides:



Advertisements
Similar presentations
DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Advertisements

Vertical versus Decentralized TB Pharmaceutical Management
Dr R.Reesaul Chest Physician Chest Clinic P. D`or Hospital
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs Using the Compendium to Plan for Monitoring and Evaluation of NTPs.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Revised National Tuberculosis Control Programme (RNTCP)
Management of the Tuberculosis Drug Supply Module 13 – March 2010.
Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.
Selection of TB Medicines & Supplies PSM Workshop to Develop GFATM PSM plans for HIV, TB and Malaria February 2006 Nairobi.
World Health Organization
Improving Access for Quality-Assured TB Medicines and Diagnostics Dr Kaspars Lunte Team Leader Sourcing and Special Projects, GDF Copenhagen, IPC Meeting.
1 Tuberculosis Drug Issues: Fixed Dose Combination Products Second Line Drugs, and Prices, Richard Laing, Kelly McGoldrick Boston University School of.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
Cost as a Barrier to Access: Identifying the Component Costs of Essential Medicines Levison L,Laing RL.
Introduction to Elements of In-Country Drug Management with Focus on TB Drugs Jim Rankin Director, Center for Pharmaceutical Management Management Sciences.
“The causes of Anti-TB medicines shortages in EMR countries and how to avoid them in the future” Khaled Sultan Drug Management Technical Officer, STOP.
DOTS Expansion: Monitoring Drugs Leopold Blanc TBS, Stop TB WHO, Communicable Diseases.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Good Procurement Practices in National TB Programs
Development and evaluation of software to support prescribing and drug supply management in the treatment of MDR-TB in Peru. Fraser H, Choi S, Jazayeri.
1 Oct 2005 WHO/STB/THD World Health Organization 4 th Meeting of Subgroup on laboratory capacity strengthening Paris, France, October Ernesto Jaramillo.
DOTS-PLUS IN TANZANIA: PREPARATION PHASE Global DOTS Expansion Working Group Meeting, Paris: 28 October 2004 NTLP - MOH Prepared by: Dr. S. M. Egwaga NTLP.
VOLUNTARY POOLED PROCUREMENT AND CAPACITY BUILDING SERVICES MICK MATTHEWS CIVIL SOCIETY OFFICER THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA.
Treating MDR-TB A Challenge Throughout ECA Public Health Practice II.
International Health Policy Program -Thailand Policy decision on multi drug resistant(MDR), extreme drug resistant(XDR) tuberculosis screening: How it.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Overview of 2000 Survey of TB Drug Supply Experiences in Low- and Middle-Income WHO Member States Diana Weil Senior Public Health Specialist World Bank/United.
Public Health. TB-DOTS program Government commitment Case detection by DSSM among symptomatic patients self-reporting to health services Standard short-course.
Trials and evidence in relation to health policy: The case of tuberculosis in Nepal and India Ian Harper.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
World Health Organization "3 by 5" Target Treat 3 million by 2005.
Access to anti-TB medicines WHO/EDM Technical briefing seminar for international staff active in pharmaceutical support programmes Salle G, WHO HQ 30.
Quantification from a TB Perspective PSM Workshop to Develop GFATM PSM plans for HIV, TB and Malaria February 2006, Nairobi.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Drug Management of Second-line anti-TB drugs through the Green Light Committee mechanism for programmes funded by the Global Fund to Fight Against AIDS,
Introducing fixed dose combination tablets into DR CONGO using the Global TB Drug Facility.
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
Roundtable. Detection and treatment of TB Andrew Black.
Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.
Selection of TB Medicines and Supplies. Unit Objective QUAN 1 Understand basic principles of selection of appropriate formulations of essential tuberculosis.
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.
Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.
Tuberculosis. TB is a common infectious disease caused by the bacterium Mycobacterium tuberculosis. The bacteria usually affects the lungs but it can.
Antituberculous treatment.
World Tuberculosis Day 2014
Global Drug Facility An innovative approach to supplying anti-TB drugs
Increased access to quality TB drugs
Change in malaria treatment policy: A study of its immediate effects on hospital malaria drug management, utilization of hospital facilities and prescription.
اپيدميولوژي و كنترل سِل
World Tuberculosis Day 2016
World Tuberculosis Day 2014
Impact of Using Fixed Dose Combinations (FDCs) versus
Impact of Using Fixed Dose Combinations (FDCs) versus
INTRODUCTION OF FDCs: NTP POLICIES, INTERVENTIONS AND EXPERIENCE Shah S. K., Sadiq H., Ahmad N., Shaikh U & Kazi G. N. National TB Control Programme,
INTRODUCTION OF FDCs: NTP POLICIES, INTERVENTIONS AND EXPERIENCE Shah S. K., Sadiq H., Ahmad N., Shaikh U & Kazi G. N. National TB Control Programme,
TB epidemiological situation in Kyrgyzstan
Introducing fixed dose combination tablets into DR CONGO using the Global TB Drug Facility
From TB control to integrated respiratory disease control
Global Drug Facility: Providing Access to Medicines and Commodities for Tuberculosis Thomas Moore Manager GDF Geneva, 19 November 2009.
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Treatment of Drug Resistant TB - Questions
Pharmacy Sector SECTOR COMMITMENT TO END TB
National Medicines Policies
Monitoring and Evaluation: A Review of Terms
Preventing recurrent TB in high HIV-prevalent areas
Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,
Presentation transcript:

Tuberculosis Drug Issues: Fixed Dose Combination Products Second Line Drugs, and Prices, Richard Laing, Kelly McGoldrick Boston University School of Public Health

Overview of TB Drug Issues Since streptomycin became available in 1948 drugs have become the mainstay of TB control But low cure rates occur because of poor access or compliance Leading to the emergence of Multiple drug resistant Tuberculosis (MDRTB)

Fixed Dose Combinations (FDC’s) WHO and IUATLD now recommend FDC’s for treatment of all new cases of TB Justification Simplicity of treatment Improved compliance Logistic ease Prevent MDR “FDC s will facilitate and support DOTS programs. They are not an alternative!”

Fixed Dose Combinations (FDC’s) continued Not Combo packs but 2,3 or 4 drugs in a single tablet Problem of bioavailability of rifampicin in some formulations identified by Acocella WHO have defined a standard formulation and abbreviated protocol for bioavailability standards, also reference laboratories Concern about cost but 2 drug FDC stable or decreased in price

Prices of Two Drug FDC over time

Drugs for Multiple Drug Resistant TB - A global problem

MDRTB Drug Issues In many countries treatment failures are treated with WHO Category 2 regimen (same four drugs plus one more) If this fails nothing to be done BUT this approach if combined with effective DOTS will inevitably lead to an increase in MDRTB resistant to five or more drugs

DOTS Plus as a response to MDRTB WHO have included MDRTB drugs in next Model Drug List but not in main list! Selected Drugs- capreomycin kanamycin cycloserine ciprofloxacin para-aminosalicylic acid (PAS) ethionamide l evofloxacin ofloxacin amikacin

Components of a DOTS + Program Political Will and support of relevant government bodies Access to adequate laboratory facilities for smear microscopy, culture and drug susceptibility testing Directly observed therapy Uninterrupted supply of first and second line drugs Use of reliable monitoring system to assess outcomes Operational research to identify constraints to implementation

Drug Issues in DOTS Plus Standardized or Customized regimens? Peru did very well with customized regimens South Africa did better with standardized but overall cure rates lower Treatment manual available on Web at URL http://www.pharmweb.net/pwmirror/library/tbres/drugres1.pdf Concern that no new drugs in pipeline

TB Drug Prices Drug Prices are determined by many factors: Company Prices Registration fees Customs duties Taxes National and local Markups wholesaler to retailer & retailer to patient Other charges

Survey of TB Drug Prices -Results Time series First Line Drugs Rate of Price Increase per year US Private 10.66% US Public 4.1% International -2%

Time series

Time series

Time series

Time series - Second Line Drugs Smaller Numbers of suppliers Average annual Rate of Increase: US Private 6.5% year US Public 2% year Exception is Kannamycin which has fallen in price

Time series

Times series

Comparison of TB Drug Prices by Country and Sector For first line max:min drug price ratio varies from 115 to 27 times US Private sector the most expensive except for Isoniazid where Japan most expensive US Public sector nearly always more expensive that public or private sector in other countries

TB Drug Prices Comparison

TB Drug Prices Comparison

TB Drug Prices Comparison - Second Line Drugs Differences not so marked because no international tenders or non profit suppliers Max:Min ratio from 2.2 to 6.6 times for various drugs

TB Drug Prices Comparison

TB Drug Prices Comparison

Tuberculin PPD Though not strictly a drug tuberculin is procured like a drug Dramatic recent increase in price

Discussion Free market works for first line drugs outside US Barrier to access is high registration fees Second line drugs not a free market because of limited number of suppliers During 2000 likely to see non-profit suppliers and pooled procurement bring prices down

Managing TB Drug Supply Selection limited list based on FDC’s Procurement Restricted tender with prequalification and performance monitoring Distribution Use private sector or NTP store Rational Use Basis of DOT, prevent misuse of TB drugs for other diseases such as chlamydae

Global Drug Facility Provides a grant and purchasing facility Can purchase TB drugs using Global Fund money directly from GDF Accessible Web Site http://www.stoptb.org/GDF/default.asp

Conclusion Ensuring reliable supply of quality assured TB drugs at best possible price is aim of any TB program TB managers will need to become more aware of TB drug supply issues Outlook is promising - FDC’s coming MDRTB drugs as part of DOTS + likely at better prices Will require international support